GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Equity-to-Asset

Heidelberg Pharma AG (XTER:HPHA) Equity-to-Asset : 0.73 (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Heidelberg Pharma AG's Total Stockholders Equity for the quarter that ended in Feb. 2024 was €45.11 Mil. Heidelberg Pharma AG's Total Assets for the quarter that ended in Feb. 2024 was €61.67 Mil. Therefore, Heidelberg Pharma AG's Equity to Asset Ratio for the quarter that ended in Feb. 2024 was 0.73.

The historical rank and industry rank for Heidelberg Pharma AG's Equity-to-Asset or its related term are showing as below:

XTER:HPHA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.2   Med: 0.72   Max: 0.91
Current: 0.73

During the past 13 years, the highest Equity to Asset Ratio of Heidelberg Pharma AG was 0.91. The lowest was -0.20. And the median was 0.72.

XTER:HPHA's Equity-to-Asset is ranked better than
56.51% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs XTER:HPHA: 0.73

Heidelberg Pharma AG Equity-to-Asset Historical Data

The historical data trend for Heidelberg Pharma AG's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Equity-to-Asset Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.66 0.31 0.66 0.70

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.65 0.69 0.70 0.73

Competitive Comparison of Heidelberg Pharma AG's Equity-to-Asset

For the Biotechnology subindustry, Heidelberg Pharma AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Equity-to-Asset falls into.



Heidelberg Pharma AG Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Heidelberg Pharma AG's Equity to Asset Ratio for the fiscal year that ended in Nov. 2023 is calculated as

Equity to Asset (A: Nov. 2023 )=Total Stockholders Equity/Total Assets
=49.34/70.353
=0.70

Heidelberg Pharma AG's Equity to Asset Ratio for the quarter that ended in Feb. 2024 is calculated as

Equity to Asset (Q: Feb. 2024 )=Total Stockholders Equity/Total Assets
=45.114/61.666
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG  (XTER:HPHA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Heidelberg Pharma AG Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines